Skip to Content

Results of OlympiA are practice changing in treatment of breast cancer

Adjuvant olaparib treatment significantly improves invasive disease-free survival in women with BRCA mutation and high-risk HER2-negative breast cancer. With a median follow-up of 2.5 years, olaparib-treated patients had a 42% reduction in the risk of developing invasive relapse compared to placebo.

Self Diagnosis Of Early Breast Cancer

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Back to top